[go: up one dir, main page]

MX2018006875A - Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab. - Google Patents

Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.

Info

Publication number
MX2018006875A
MX2018006875A MX2018006875A MX2018006875A MX2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A
Authority
MX
Mexico
Prior art keywords
antibody
avelumab
pharmaceutical formulation
death
receiver
Prior art date
Application number
MX2018006875A
Other languages
English (en)
Other versions
MX389289B (es
Inventor
Del Rio Alessandra
Rinaldi Gianluca
FRATARCANGELI Silvia
Weigandt Markus
Voss Senta
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54838201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018006875A publication Critical patent/MX2018006875A/es
Publication of MX389289B publication Critical patent/MX389289B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación de anticuerpo anti-PD-L1 novedosa. En particular, la invención se refiere a una formulación farmacéutica acuosa del anticuerpo anti-PD-L1 Avelumab.
MX2018006875A 2015-12-07 2016-12-05 Formulación farmacéutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab. MX389289B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15198233 2015-12-07
PCT/EP2016/002040 WO2017097407A1 (en) 2015-12-07 2016-12-05 Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab

Publications (2)

Publication Number Publication Date
MX2018006875A true MX2018006875A (es) 2018-11-09
MX389289B MX389289B (es) 2025-03-20

Family

ID=54838201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006875A MX389289B (es) 2015-12-07 2016-12-05 Formulación farmacéutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.

Country Status (34)

Country Link
US (2) US11058769B2 (es)
EP (2) EP3747466A1 (es)
JP (1) JP6925337B2 (es)
KR (1) KR102697026B1 (es)
CN (1) CN108367072B (es)
AR (1) AR107014A1 (es)
AU (1) AU2016368099C1 (es)
CA (1) CA3007481C (es)
CL (1) CL2018001488A1 (es)
CO (1) CO2018005525A2 (es)
CY (1) CY1123358T1 (es)
DK (1) DK3386541T3 (es)
EA (1) EA201891339A1 (es)
ES (1) ES2823279T3 (es)
HR (1) HRP20201573T1 (es)
HU (1) HUE050811T2 (es)
IL (1) IL259563B (es)
LT (1) LT3386541T (es)
MX (1) MX389289B (es)
MY (1) MY195681A (es)
NZ (1) NZ743964A (es)
PE (1) PE20181400A1 (es)
PH (1) PH12018500894A1 (es)
PL (1) PL3386541T3 (es)
PT (1) PT3386541T (es)
RS (1) RS61029B1 (es)
SA (1) SA518391743B1 (es)
SG (1) SG11201804758QA (es)
SI (1) SI3386541T1 (es)
SM (1) SMT202000497T1 (es)
TW (1) TWI630917B (es)
UA (1) UA123270C2 (es)
WO (1) WO2017097407A1 (es)
ZA (1) ZA201804534B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624298B2 (en) * 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
UA123270C2 (uk) 2015-12-07 2021-03-10 Мерк Патент Гмбх Водний фармацевтичний препарат, який містить антитіло до pd-l1 авелумаб
CN108350082B (zh) 2016-06-13 2021-09-24 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
SG11201908091QA (en) * 2017-03-06 2019-10-30 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
WO2019124946A1 (ko) * 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
WO2020060183A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 트라스투주맙 항체 안정화 액체 제제
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
PH12021551916A1 (en) 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.
JP2022540781A (ja) * 2019-06-25 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ４７／ｐｄ‐ｌ１二重特異性抗体を含む製剤、その調製方法及び使用
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
US12121565B2 (en) 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
US12380963B2 (en) 2019-10-14 2025-08-05 The Medical College Of Wisconsin, Inc. Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
WO2021087105A1 (en) 2019-10-30 2021-05-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
CN114846135A (zh) 2019-11-04 2022-08-02 杜克大学 原发性和转移性癌症的治疗
KR20220115803A (ko) * 2019-12-13 2022-08-18 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CA3164600A1 (en) * 2019-12-18 2021-06-24 Tesaro, Inc. Biopharmaceutical compositions and related methods
KR102683876B1 (ko) * 2020-11-11 2024-07-11 가톨릭대학교 산학협력단 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
KR20250140097A (ko) 2023-01-30 2025-09-24 키맵 리미티드 항체

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT1934236E (pt) 2005-09-02 2012-12-26 Glycomimetics Inc Inibidores de pan-selectina heterobifuncionais
CA2634547C (en) * 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
SMT202500126T1 (it) * 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102686241A (zh) * 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
SI2691112T1 (en) * 2011-03-31 2018-07-31 Merck Sharp & Dohme Corp. STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
US9624298B2 (en) * 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
AU2014324703C1 (en) * 2013-09-27 2020-10-29 Genentech, Inc. Anti-PDL1 antibody formulations
AU2014337263B2 (en) * 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
WO2016181348A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
MX390878B (es) 2015-06-16 2025-03-21 Merck Patent Gmbh Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
EP3355902B1 (en) 2015-09-30 2022-04-13 Merck Patent GmbH Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
UA123270C2 (uk) 2015-12-07 2021-03-10 Мерк Патент Гмбх Водний фармацевтичний препарат, який містить антитіло до pd-l1 авелумаб
SG11201908091QA (en) 2017-03-06 2019-10-30 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation

Also Published As

Publication number Publication date
CN108367072B (zh) 2022-12-27
WO2017097407A1 (en) 2017-06-15
EP3747466A1 (en) 2020-12-09
HK1257781A1 (zh) 2019-10-25
KR102697026B1 (ko) 2024-08-20
SG11201804758QA (en) 2018-07-30
SA518391743B1 (ar) 2022-12-01
DK3386541T3 (da) 2020-09-28
CN108367072A (zh) 2018-08-03
PH12018500894A1 (en) 2018-11-05
SI3386541T1 (sl) 2020-11-30
US11058769B2 (en) 2021-07-13
JP6925337B2 (ja) 2021-08-25
SMT202000497T1 (it) 2021-01-05
IL259563A (en) 2018-07-31
EP3386541A1 (en) 2018-10-17
UA123270C2 (uk) 2021-03-10
RS61029B1 (sr) 2020-12-31
US20210100903A1 (en) 2021-04-08
TW201725051A (zh) 2017-07-16
KR20180085801A (ko) 2018-07-27
EP3386541B1 (en) 2020-07-08
EA201891339A1 (ru) 2019-01-31
LT3386541T (lt) 2020-10-26
CA3007481C (en) 2024-01-30
CY1123358T1 (el) 2021-12-31
PE20181400A1 (es) 2018-09-07
AU2016368099C1 (en) 2023-10-12
ES2823279T3 (es) 2021-05-06
AU2016368099B2 (en) 2023-03-09
US20180369377A1 (en) 2018-12-27
ZA201804534B (en) 2020-11-25
HRP20201573T1 (hr) 2020-12-11
IL259563B (en) 2021-05-31
HUE050811T2 (hu) 2021-01-28
JP2018536676A (ja) 2018-12-13
MX389289B (es) 2025-03-20
AU2016368099A1 (en) 2018-07-19
MY195681A (en) 2023-02-03
PT3386541T (pt) 2020-10-12
AR107014A1 (es) 2018-03-14
CO2018005525A2 (es) 2018-08-10
PL3386541T3 (pl) 2021-04-06
CL2018001488A1 (es) 2018-09-14
CA3007481A1 (en) 2017-06-15
BR112018010211A2 (pt) 2019-02-05
TWI630917B (zh) 2018-08-01
NZ743964A (en) 2023-03-31

Similar Documents

Publication Publication Date Title
MX2018006875A (es) Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
CL2018001953A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
IL269002A (en) Antibodies against pd-l1
IL263834A (en) Anti-pd-l1 antibodies
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
FR25C1022I1 (fr) Anticorps anti-pd-1
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112017011234A2 (pt) anticorpos contra receptor da barreira hematoencefálica e métodos de uso
EP3334824A4 (en) PD-1 ANTIBODY
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX390385B (es) Anticuerpos anti-pd-l1.
BR112017006137A2 (pt) formulação que contém biotensoativo
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
MX2017000985A (es) Anticuerpos anti-pd-1.
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016012530A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
EP3441086A4 (en) MONOCLONAL ANTI-PD-1 ANTIBODY
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
EP3383915A4 (en) PD-1 ANTIBODY
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
BR112016025056A2 (pt) uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
EA201790392A1 (ru) Фармацевтическая упаковка